1. Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors
   A. S. Yamashita et al, 2014, Journal of Neuro-Oncology CrossRef
2. TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions
   GUN-HOO PARK et al, 2014, Oncology Reports CrossRef
3. NF1, Neurofibromin and Gene Therapy: Prospects of Next-Generation Therapy
   Xi-Wei Cui et al, 2020, Current Gene Therapy CrossRef
4. Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor
   Gun-Hoo Park et al, 2021, International Journal of Molecular Sciences CrossRef
5. BNIP3 Regulates AT101 [(-)-Gossypol] Induced Death in Malignant Peripheral Nerve Sheath Tumor Cells
   Niroop Kaza et al, 2014, PLoS ONE CrossRef
6. Wilms’ Tumor Gene 1 (WT1) Silencing Inhibits Proliferation of Malignant Peripheral Nerve Sheath Tumor sNF96.2 Cell Line
   Rosalba Parenti et al, 2014, PLoS ONE CrossRef
7. Sec6/8 regulates Bcl-2 and Mcl-1, but not Bcl-xl, in malignant peripheral nerve sheath tumor cells
   Toshiaki Tanaka et al, 2016, Apoptosis CrossRef
8. Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors in a Neurofibromin-Dependent Manner
   Garrett Alewine et al, 2022, Journal of Personalized Medicine CrossRef
9. Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance
   Eunyoung Tak et al, 2021, Oncology Reports CrossRef